Tag: CLEC1
OSE Immunotherapeutics presents the latest data on the BiCKI®IL-7, CLEC-1 and OSE-230 preclinical programs in Immuno-Oncology and Immuno-Inflammation At international conferences – 06/15/2023 at 07:30
Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations…
OSE Immuno: publication in Science Advances of data on CLEC-1, its new myeloid immune checkpoint
By Hector Chaunu Posted on 11/21/2022 at 8:46 p.m. Photo credit © ChaunuPictures …
OSE Immunotherapeutics announces the publication in Science Advances of data on CLEC-1, its new myeloid immune checkpoint – 2022-11-21 at 18:00
Nantes, France – November 21, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the publication in the peer-reviewed journal Science Advances of data from a…
OSE Immunotherapeutics presents advances in its Immuno-Oncology programs, BiCKI®-IL-7v and CLEC-1, at international conferences – 2022-10-12 at 18:00
Nantes, France – October 12, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that three abstracts have been accepted for poster presentation at the 37th annual…
Ose immuno: A European patent for CLEC-1
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
OSE Immuno: a European patent for CLEC-1
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…
OSE Immuno: a European patent for CLEC-1 – 05/02/2022 at 09:45
(CercleFinance.com) – OSE Immunotherapeutics announces that the European Patent Office (EPO) has granted a new patent which strengthens the protection of CLEC-1, its new myeloid checkpoint inhibitor target, and its…